user

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Clinical benefit observed in 55% of patients receiving HS-110 plus nivolumab after checkpoint inhibitor treatment failureHS-110 in combination with nivolumab...

error: Content is protected !!